Search

Your search keyword '"Benini, Camilla"' showing total 37 results
Start Over Author "Benini, Camilla" Publication Year Range Last 10 years
37 results on '"Benini, Camilla"'

6. Bone Loss in Inflammatory Rheumatic Musculoskeletal Disease Patients Treated With Low‐Dose Glucocorticoids and Prevention by Anti‐Osteoporosis Medications.

Author

Adami, Giovanni, Fassio, Angelo, Rossini, Maurizio, Benini, Camilla, Pistillo, Francesca, Viapiana, Ombretta, Bertelle, Davide, and Gatti, Davide

Subjects
DRUG therapy for rheumatism, OSTEOPOROSIS prevention, GLUCOCORTICOIDS, LOG-rank test, MULTIVARIATE analysis, MANN Whitney U Test, OSTEOPOROSIS, ANTIRHEUMATIC agents, T-test (Statistics), KAPLAN-Meier estimator, DESCRIPTIVE statistics, BONE density, LOGISTIC regression analysis, DATA analysis software, LONGITUDINAL method, PROPORTIONAL hazards models
Abstract

Objective: The negative effects of glucocorticoids on bone depend on dose and treatment duration. However, it is unclear whether a safe dose exists, especially for patients with inflammatory rheumatic musculoskeletal diseases (iRMDs). We undertook this study to determine the effects of glucocorticoid doses on bone health in iRMD patients. Methods: We conducted a longitudinal cohort study on women with iRMD. Bone mineral density (BMD) and fractures were assessed prospectively and compared to a matched cohort without iRMD. Kaplan‐Meier curves with log rank test were made for iRMD patients (stratified for glucocorticoid use and dose) and the matched cohort. Multivariable Cox regression survival models were also employed to analyze the effect of glucocorticoids on fracture. Results: A total of 884 women with iRMD and 1,766 controls (matched for age, T score, and 10‐year fracture risk) were included in the study and followed up for up to 6 years. BMD decreased significantly in all patients receiving glucocorticoids who were not receiving anti‐osteoporosis treatment (–4.26% for ≥5 mg/day of prednisone equivalent, P = 0.0011; –4.23% for 2.5–5 mg/day, P = 0.0422; –2.66% for 0–2.5 mg/day, P = 0.0006). Anti‐osteoporosis treatment (largely bisphosphonates) prevented bone loss only in patients receiving <5 mg/day of prednisone equivalent. Fracture incidence was higher in patients with iRMD compared to controls, but only glucocorticoid doses ≥5 mg/day were associated with significantly higher risk of fracture. Conclusion: Glucocorticoid doses as low as 2.5 mg/day were associated with BMD loss in iRMD patients, but this effect was preventable. BMD loss in patients receiving ≥5 mg/day was not totally prevented by anti‐osteoporosis medications currently used in clinical practice, resulting in higher risk of fracture. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

7. Factors associated with radiographic progression in rheumatoid arthritis starting biological diseases modifying anti-rheumatic drugs (bDMARDs).

Author

Adami, Giovanni, Fassio, Angelo, Pistillo, Francesca, Benini, Camilla, Viapiana, Ombretta, Rossini, Maurizio, and Gatti, Davide

Subjects
ANTIRHEUMATIC agents, RHEUMATOID arthritis, RADIOGRAPHY, INFLAMMATION, BIOLOGICALS
Abstract

Background: Biological DMARDs (bDMARDs) have been proven to prevent joint damage and bone erosions. Nevertheless, approximately 15% of rheumatoid arthritis (RA) patients on bDMARDs will progress despite good control of joint inflammation. Objectives: The objective of our study is to investigate the factors associated with radiological progression of patients treated with bDMARDs. Design: We conducted a retrospective analysis of longitudinally collected data on RA patients starting bDMARDs. Methods: Presence or development of new erosions was assessed by a skilled rheumatologist at the time of the visit (baseline and 12 months thereafter). To determine the predictors of erosions, we employed multivariable logistic regression models. Discriminatory capacity for the prediction of new erosion development was assessed with receiver operating characteristic (ROC) curve, which was based on the logistic regression model. Results: A total of 578 RA patients starting bDMARDs were included in the study. Overall, 46 patients (approximately 10%) had radiographic progression (at least one new erosion) at 12 months of follow-up. The factors independently associated with higher risk of developing new erosions while on bDMARD were younger age, high disease activity at baseline, not being treated with cDMARDs, and presenting with erosions at baseline. In addition, we built a predictive model that can accurately foresee new erosions (AUC 0.846) in patients receiving bDMARDs Conclusion: We found that baseline erosive disease, higher disease activity during treatment, younger age, and monotherapy were the factors independently associated with the development of bone erosions. Our study may inform future targeted intervention in RA patients at risk of radiographic progression. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Effects on Serum Inflammatory Cytokines of Cholecalciferol Supplementation in Healthy Subjects with Vitamin D Deficiency

Author

Fassio, Angelo, primary, Gatti, Davide, additional, Rossini, Maurizio, additional, Bertelle, Davide, additional, Bixio, Riccardo, additional, Viapiana, Ombretta, additional, Milleri, Stefano, additional, Benini, Camilla, additional, Pistillo, Francesca, additional, Zanetti, Giulia, additional, and Adami, Giovanni, additional

Published
2022
Full Text
View/download PDF

19. sj-docx-1-tab-10.1177_1759720X221105009 – Supplemental material for Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study

Author

Adami, Giovanni, Gavioli, Irene, Rossini, Maurizio, Viapiana, Ombretta, Orsolini, Giovanni, Benini, Camilla, Bertoldo, Eugenia, Fracassi, Elena, Gatti, Davide, and Fassio, Angelo

Subjects
FOS: Clinical medicine, 110604 Sports Medicine, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110314 Orthopaedics
Abstract

Supplemental material, sj-docx-1-tab-10.1177_1759720X221105009 for Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study by Giovanni Adami, Irene Gavioli, Maurizio Rossini, Ombretta Viapiana, Giovanni Orsolini, Camilla Benini, Eugenia Bertoldo, Elena Fracassi, Davide Gatti and Angelo Fassio in Therapeutic Advances in Musculoskeletal Disease

Published
2022
Full Text
View/download PDF

31. FRI0469 CHANGES IN DKK-1, SCLEROSTIN, AND RANKL SERUM LEVELS FOLLOWING DISCONTINUATION OF LONG-TERM DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN

Author

Adami, Giovanni, primary, Fassio, Angelo, additional, Benini, Camilla, additional, Vantaggiato, Elisabetta, additional, Saag, Kenneth, additional, Giollo, Alessandro, additional, Lippolis, Irma, additional, Idolazzi, Luca, additional, Orsolini, Giovanni, additional, Rossini, Maurizio, additional, and Gatti, Davide, additional

Published
2019
Full Text
View/download PDF

33. Quantitative chest computed tomography is associated with two prediction models of mortality in interstitial lung disease related to systemic sclerosis

Author

Ariani, Alarico, primary, Silva, Mario, additional, Seletti, Valeria, additional, Bravi, Elena, additional, Saracco, Marta, additional, Parisi, Simone, additional, De Gennaro, Fabio, additional, Idolazzi, Luca, additional, Caramaschi, Paola, additional, Benini, Camilla, additional, Bodini, Flavio Cesare, additional, Scirè, Carlo Alberto, additional, Carrara, Greta, additional, Lumetti, Federica, additional, Alfieri, Veronica, additional, Bonati, Elisa, additional, Lucchini, Gianluca, additional, Aiello, Marina, additional, Santilli, Daniele, additional, Mozzani, Flavio, additional, Imberti, Davide, additional, Michieletti, Emanuele, additional, Arrigoni, Eugenio, additional, Delsante, Giovanni, additional, Pellerito, Raffaele, additional, Fusaro, Enrico, additional, Chetta, Alfredo, additional, and Sverzellati, Nicola, additional

Published
2017
Full Text
View/download PDF

34. Operator-independent quantitative chest computed tomography versus standard assessment of interstitial lung disease related to systemic sclerosis: A multi-centric study

Author

Ariani, Alarico, primary, Silva, Mario, additional, Bravi, Elena, additional, Saracco, Marta, additional, Parisi, Simone, additional, De Gennaro, Fabio, additional, Lumetti, Federica, additional, Idolazzi, Luca, additional, Seletti, Valeria, additional, Caramaschi, Paola, additional, Benini, Camilla, additional, Bodini, Flavio Cesare, additional, Scirè, Carlo Alberto, additional, Lucchini, Gianluca, additional, Santilli, Daniele, additional, Mozzani, Flavio, additional, Imberti, Davide, additional, Arrigoni, Eugenio, additional, Delsante, Giovanni, additional, Pellerito, Raffaele, additional, Fusaro, Enrico, additional, and Sverzellati, Nicola, additional

Published
2015
Full Text
View/download PDF

36. New Strategies for the Prevention and Treatment of Systemic and Local Bone Loss; from Pathophysiology to Clinical Application

Author

Fassio, Angelo, Rossini, Maurizio, Viapiana, Ombretta, Idolazzi, Luca, Vantaggiato, Elisabetta, Benini, Camilla, and Gatti, Davide

Abstract

Bone loss is the result of a negative unbalance between bone formation ad bone resorption. In the last years, the studies on the Wnt canonical pathway have highlighted its crucial role in bone balance through its influence on the activity and maturation of the osteoblast line and in the Receptor Activator of Nuclear Factor Κ B (RANK) - RANK ligand (RANKL)/Osteoprotegerin (OPG) system. These mechanisms are involved not only in the pathological processes inducing not only systemic bone loss (i.e. Postmenopausal osteoporosis, glucocorticoid- induced osteoporosis, etc.), but also at a local level, as happens in Rheumatoid Arthritis (RA). Recently, several new drugs for the treatment of bone loss have been approved, while some others are still under development. The most promising new drugs in the treatment of osteoporosis include the antibody that neutralizes RANKL (denosumab, DMAb), monoclonal antibodies against sclerostin and parathyroid hormone-related protein analogue. Other new strategies for the prevention and treatment of bone loss include calcilytics, cathepsin K inhibitor or the combination or the sequential use of the current drugs. New insights concerning the treatment of the local bone loss in RA and in Complex Regional Pain Syndrome type I are also provided in this review.

Published
2017
Full Text
View/download PDF

37. Long-term effectiveness and predictors of bisphosphonate treatment in type I complex regional pain syndrome.

Author

Adami G, Fassio A, Rossini M, Montanari F, Manfrè S, Bonasera G, Bertelle D, Benini C, Viapiana O, Braga V, and Gatti D

Subjects
Humans, Male, Female, Middle Aged, Treatment Outcome, Longitudinal Studies, Adult, Time Factors, Aged, Risk Factors, Hyperalgesia drug therapy, Hyperalgesia physiopathology, Diphosphonates therapeutic use, Reflex Sympathetic Dystrophy drug therapy, Reflex Sympathetic Dystrophy diagnosis, Reflex Sympathetic Dystrophy physiopathology, Pain Measurement, Bone Density Conservation Agents therapeutic use, Bone Density Conservation Agents adverse effects
Abstract

Objectives: Complex regional pain syndrome (CRPS) is a painful disease that leads to chronic pain and disability. Bisphosphonates are largely used in the real-life for the treatment of CRPS, but data on long-term effectiveness and its predictors are lacking., Methods: We conducted a longitudinal observational study on patients with type I CRPS treated with IV neridronate (100 mg on 4 occasions). Clinical and demographic characteristics were collected at baseline, after 3 months (M3) and after 12 months (M12). Multivariable logistic regression was employed to determine the factors associated with long-term response to treatment., Results: 103 patients with type I CRPS treated with IV neridronate were included in the study. Mean VAS pain at baseline was 79.1 mm and decreased significantly at M3 (-45.9 mm, 95% CI 40.1 to 51.8) and M12 (-61.6 mm, 95% CI 55.3 to 67.9). Hyperalgesia and allodynia resolved in 84.3% and 88.1% of patients at M12. Loss of motion resolved in 53.5% of patients. The predictors of excellent response were gender (male better), predisposing event to CRPS (no event being better than any predisposing event), site of CRPS (lower limb being better), and early response at M3 on VAS pain (2.5 times the chance of being excellent responder every 10 mm decrease)., Conclusions: In this real-life study neridronate was associated with rapid and progressive improvement of symptoms of CRPS which was maintained up to 3 years of follow-up. The predictors of excellent response were early response, lower limb localisation, absence of predisposing events and male gender.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results